CELU CELULARITY INC

Celularity to Present at Jefferies Cell and Genetic Medicine Summit

Celularity to Present at Jefferies Cell and Genetic Medicine Summit

FLORHAM PARK, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, today announced that Robert Hariri, M.D., Ph.D., Founder, Chairman and Chief Executive Officer of Celularity, will present at the Jefferies Cell and Genetic Medicine Summit on Friday, September 30, 2022 at 11 a.m. ET.

A live webcast of the presentation can be accessed on the Investors section of Celularity’s website at . A replay of the webcast will be archived and available following the event for approximately 30 days.

About Celularity

Celularity Inc. (Nasdaq: CELU) headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing allogeneic cryopreserved off-the-shelf placental-derived cell therapies, including therapeutic programs using unmodified natural killer (NK) cells, genetically modified NK cells, T-cells engineered with a CAR (CAR T-cells), and mesenchymal-like adherent stromal cells (ASCs). These therapeutic programs target indications in cancer, infectious and degenerative diseases. In addition, Celularity develops and manufactures innovative biomaterials also derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.

To learn more, visit celularity.com.

Celularity Investor Contacts:

Carlos Ramirez SVP, Investor Relations

Celularity Inc.

 



EN
27/09/2022

Underlying

CELUCELULARITY INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CELULARITY INC

 PRESS RELEASE
Free
CELU CELULARITY INC

Celularity & Fountain Life Announce Partnership to Deliver Stem Cell T...

Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law Fountain Life operates four flagship longevity centers, including two in Florida, where a new state law effective July 1, 2025, authorizes licensed physicians to administer stem cell therapies to members with conditions in orthopedics, wound care, and pain management. FLORHAM PARK, N.J., July 09, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company focused on addressing age-related and degenerative diseases, announced today t...

July 9, 2025 1 EN
 PRESS RELEASE
Free
CELU CELULARITY INC

Celularity Hails New Florida Law Opening Patient Access to Stem Cell T...

Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies New law goes into effect on July 1st authorizing Florida physicians to provide stem cell therapies to their patients for orthopedics, wound care, and pain management  FLORHAM PARK, N.J., July 01, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, today hailed a new Florida law taking effect today that opens the door to physicians’ use of investigational stem cell therapies in the state in orthopedics, wound care, and pain manag...

July 1, 2025 1 EN
 PRESS RELEASE
Free
CELU CELULARITY INC

Celularity Announces Chief Financial Officer Transition

Celularity Announces Chief Financial Officer Transition Celularity retains financial and business advisor to provide outsourced accounting and consulting services during the transition period FLORHAM PARK, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, today announced that it terminated the employment of its Chief Financial Officer (“CFO”), David Beers, effective immediately. Mr. Beer’s termination was not related to the Company’s financial or operating results or to any disagreements ...

June 10, 2025 1 EN
 PRESS RELEASE
Free
CELU CELULARITY INC

Celularity Announces Publication Advancing Ocular Surface Reconstructi...

Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology Highlights the unique potential of Celularity’s proprietary advanced biomaterial technology as a novel cellular delivery system for ocular surface reconstructionSupports broad range of regenerative medicine applications beyond ophthalmology FLORHAM PARK, N.J., June 02, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, today announced its research published in the May 29, 2025, issue of the...

June 2, 2025 1 EN
 PRESS RELEASE
Free
CELU CELULARITY INC

Celularity Receives Nasdaq Notice Regarding Form 10-Q

Celularity Receives Nasdaq Notice Regarding Form 10-Q FLORHAM PARK, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a cellular and regenerative medicine company, today announced that on May 28, 2025, Nasdaq notified the Company that it did not timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2025. Based on this latest notice, the Company is not in compliance with Listing Rule 5250 (c)(1), which requires the Company to timely file all required periodic financial reports with the Securities and Exchange Commi...

May 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch